FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Naproxen

Drug and asset intelligence for Naproxen with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Hetero Labs →

Recent signals(2)

RegulatoryJuly 9, 2026

FDA Grants AP Status for Hetero Labs' Naproxen ANDA215776

The FDA has granted abbreviated approval (AP) status for Hetero Labs' ANDA for Naproxen.

RegulatoryJuly 8, 2026

FDA Accepts Supplement for Naproxen by Novitium Pharma

The FDA has accepted a supplemental application for Naproxen from Novitium Pharma.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Hetero Labs — Naproxen

July 9, 2026 · N/A

Topline Data

— Naproxen

July 8, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

NSAID →

Pain Management →

Pain Management · NSAID →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.